Oraya Therapeutics, Newark, Calif.-based minimally invasive ophthalmic treatment company, has published the results of a study analyzing the effectiveness and safety of its wet age-related macular degeneration therapy in Ophthalmology.
The INTREPID study demonstrated that Oraya Therapy Stereotactic Radiotherapy decreased the amount of anti-VEGF injections needed to treat macular degeneration patients.
More Articles on Ophthalmology:
3 Statistics on Cataract Surgery Procedure Times in ASCs
Abbott Medical Optics Appoints Dr. David Tanzer Chief Medical Officer
Hubble Telemedical Launches EyeQ Wellness Exam
The INTREPID study demonstrated that Oraya Therapy Stereotactic Radiotherapy decreased the amount of anti-VEGF injections needed to treat macular degeneration patients.
More Articles on Ophthalmology:
3 Statistics on Cataract Surgery Procedure Times in ASCs
Abbott Medical Optics Appoints Dr. David Tanzer Chief Medical Officer
Hubble Telemedical Launches EyeQ Wellness Exam